摘要
目的 :探讨吉西他滨 (Gemcitabine)联合铂类药物治疗老年中晚期非小细胞肺癌 (NSCLC)的临床疗效和毒性。方法 :予吉西他滨 (Gemcitabine) 10 0 0mg/m2 第 1、 8天静滴并联合铂类药物治疗老年非小细胞肺癌(NSCLC) 2 0例 ,三周为一治疗周期 ,两周期后评价疗效和毒副作用 ,随访缓解期和生存期。结果 :本组 2 0例病例中 ,治疗总有效 4 0 % ,中位缓解期 7个月 ,中位生存期 9个月 ,主要毒副作用为骨髓抑制和胃肠道反应。其中白细胞减少发生率为 80 % ,血小板减少发生率为 6 0 %。结论 :吉西他滨 (Gemcitabine)对老年非小细胞肺癌(NSCLC)有较好疗效 ,主要毒性反应为较严重的血液学毒性 ,老年患者最好辅以G -CSF或GM -CSF以及免疫与营养支持治疗 ,则能顺利完成化疗 ,吉西他滨 (Gemcitabine)联合铂类药物可做为老年非小细胞肺癌 (NSCLC)的一线治疗方案。
Objective:To investigate the efficacy and toxicity of Gemcitabine and Platinum Medicines in the treatment of elderly patients with middle-advanced non-small cell lung cancer.Methods:Twenty elderly patients with middle-advanced non-small cell lung cancer were treated by combination chemotherapy of Gemcitabine and Platinum Medicines for two cycles:Gemcitabine 1000mg/m 2 IV on day 1?8,every three weeks as one cycle.The response,toxicity,telievable period and survival period were evaluated.Results:The total response rate was 40%,the median relievable period was 7 months,the median duration of survival was nine months,and the major toxicity was inhibition of bone marrow and digestive reaction.The rate of decrease in leukocyte and platelet separately was 80% and 60%.Conclusion:Combination chemotherapy of Gemcitabine and Platinum medicines is effective in the treatment of elderly patients with middle-advanced non-small cell lung cancer.The main adverse effects are severe hematological toxicities.Combination chemotherapy will be completed successfully when G-CSF or GM-CSF,and immunity and nutrition used as a support treatment.Gemcitabine and Platinum can be used as first-line protocol chemotherapy in non-small cell lung cancer.
出处
《华西医学》
CAS
2004年第1期13-14,共2页
West China Medical Journal
